NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies. (December 2016) - Ardini, E.; Lombardi Borgia, A.; Texido, G.; Alzani, R.; Avanzi, N.; Amboldi, N.; Cribioli, S.; Mancini, L.; Casero, D.; Pastori, W.; Montemartini, M.; Montagnoli, A.; et al.